ada standards of care 2025 obesity pharmacotherapy glp-1 Frontiers Pharmacotherapy for obesity management in

As with other microdosing trends, GLP-1 microdosing is expected to increase in popularity, particularly among telehealth providers, according to eMarketer

To work within these parameters, originally CMS announced two models to test expanded access to GLP-1 medications for people with Medicare: the GLP-1 Bridge Program and the Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model

Importantly, ePA has demonstrated dramatic improvements: pilot programs report prior authorization requests being processed in minutes instead of days or weeks ( [6] ) ( [7] )

Semaglutide and liraglutide, which were initially approved for the treatment of type 2 diabetes, have since been approved by the Food and Drug Administration as weight loss medications due to their effectiveness in promoting significant and sustained weight loss

whole-cell and cell-internalized probe accumulated even at 120 min of incubation following the rapid increase within 30 min (Fig